Novartis CEO Backs Malaria Drug Against COVID-19
Also Testing Jakavi, Gilenya And Ilaris
A coronavirus vaccine is some way off and until then, Vas Narasimhan, head of Novartis, is thinking that of the drugs being repurposed to treat COVID-19, hydroxychloroquine looks best placed to provide the quickest benefit.
You may also be interested in...
Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.
Speaking to Scrip, Steven Baert, chief people and organization officer at Novartis, said that a company’s response to coronavirus reveals its real identity and will shape its future.
Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug
As the global number of COVID-19 cases exceeds 500,000 for the first time, more biopharma companies throw their weight behind Gates Foundation's drug-hunting initiative.